ViGenCell Inc. Logo

ViGenCell Inc.

Developing T-cell immune therapies to treat cancer and other incurable diseases.

308080 | KO

Overview

Corporate Details

ISIN(s):
KR7308080001
LEI:
Country:
South Korea
Address:
서울특별시 금천구 가산로9길 66 더리즌밸리 지식산업센터(가산동), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ViGenCell Inc. is a biotechnology company specializing in the research and development of immune cell therapies. The company develops novel treatments for cancers and other incurable diseases, aiming to prolong life expectancy and enhance patient quality of life. Its core technology includes ViTier, a proprietary T-cell therapy platform that employs antigen-specific killer T cells to target and eliminate pathogens or tumor cells. Founded in 2013 as the first subsidiary of the Catholic University Technology Holdings, ViGenCell leverages clinically validated research to advance its therapeutic pipeline.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등거래계획보고서
Korean 40.7 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.2 MB
2025-04-30 00:00
Regulatory News Service
기타경영사항(자율공시) (iPSC(유도만능줄기세포) 유래 NK세포치료제 공동개발계약 체결)
Korean 6.8 KB
2025-04-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-04-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-03-28 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 12.6 KB
2025-03-27 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 33.6 KB
2025-03-27 00:00
Board/Management Information
대표이사변경
Korean 10.6 KB
2025-03-19 00:00
Audit Report / Information
감사보고서제출
Korean 25.3 KB
2025-03-19 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 395.3 KB
2025-03-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-03-13 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 90.2 KB
2025-03-12 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 818.4 KB
2025-03-11 00:00
Share Issue/Capital Change
주식매수선택권행사
Korean 17.9 KB

Automate Your Workflow. Get a real-time feed of all ViGenCell Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ViGenCell Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ViGenCell Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Idorsia Ltd Logo
Develops and commercializes small-molecule medicines for CNS, cardiovascular, and immune disorders.
Switzerland
IDIA
IGC Pharma, Inc. Logo
Clinical-stage pharma creating Alzheimer's therapies & AI-powered diagnostics.
United States of America
IGC
IL DONG PHARMACEUTICAL CO., LTD. Logo
Develops & manufactures pharmaceuticals, APIs, and offers CMO services for various diseases.
South Korea
249420
ILSUNG IS CO., LTD. Logo
Develops pharmaceuticals like antibiotics and anesthetics, expanding into CNS and GI therapies.
South Korea
003120
ILYANG PHARMACEUTICAL CO.,LTD Logo
Develops & manufactures drugs, vaccines & supplements for oncology & gastroenterology needs.
South Korea
007570
I-Mab Logo
A clinical-stage biopharma developing immuno-oncology agents and bispecific antibodies for cancer.
United States of America
IMAB
ImageneBio, Inc. Logo
A clinical-stage biopharma pioneering therapies for immune & inflammatory diseases.
United States of America
IMA
IM Cannabis Corp. Logo
International producer of medical-grade cannabis for patients and providers in Israel and Germany.
United States of America
IMCC
Immatics N.V. Logo
Develops T-cell redirecting immunotherapies (ACT & TCR Bispecifics) for solid tumor cancers.
United States of America
IMTX
Immix Biopharma, Inc. Logo
Developing safer cell therapies for AL Amyloidosis and hematologic malignancies.
United States of America
IMMX

Talk to a Data Expert

Have a question? We'll get back to you promptly.